HRS9531

4 papers8 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

4 independent labs

Human trial4

Outcomes

Body weight

downin humans3

3 studies

HRS9531 decreases body weight in humans (-4.0% to -8.9%).
“HRS9531 induced a continuous dose-dependent body weight loss ranging from -4.0% to -8.9%.”
Human trialtype 2 diabetes mellitussubcutaneous1, 2, 3 and 4.5 mg32 weeksn = 199
Efficacy and Safety of a Novel Dual GLP-1/GIP Receptor Agonist in Participants with Type 2 Diabetes Mellitus Up to 32 Weeks
ADA Scientific Sessions 2025 abstract13 Jun 2025
HRS9531 decreases body weight in humans (-3.8 kg (4.7%) and -4.4 kg (5.4%) vs -1.6 kg (1.9%)).
“mean weight loss on Day 29 was 3.8 kg (4.7%) and 4.4 kg (5.4%) in the 10 mg and 10/25 mg groups, respectively, versus 1.6 kg (1.9%) in the placebo group.”
Human trial4 weeksn = 40
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS9531 Tablet, an Oral Dual GLP-1/GIP Receptor Agonist, in Healthy Participants—A Phase 1 Study
ADA Scientific Sessions 2025 abstract13 Jun 2025
HRS9531 decreases body weight in humans (up to 17.97% reduction vs 0.74% placebo).
“At wk 32, pts treated with HRS9531 achieved up to a 17.97% reduction in mean body weight (BW) compared to 0.74% in the PBO group”
Human trialobese adults without diabetes32 wks
Efficacy and Safety of a Novel Dual GLP-1/GIP Receptor Agonist (HRS9531), in Obese Adults without Diabetes—Up to 52-Week Treatment
ADA Scientific Sessions 2025 abstract13 Jun 2025

Systolic blood pressure

downin humans1

1 study

HRS9531 decreases systolic blood pressure in humans (up to -9.5 mmHg).
“HRS9531 was associated with improvement in systolic blood pressure, TG levels and UACR up to -9.5 mmHg, -25.7% and -61.8%, respectively.”
Human trialtype 2 diabetes mellitussubcutaneous32 weeksn = 199
Efficacy and Safety of a Novel Dual GLP-1/GIP Receptor Agonist in Participants with Type 2 Diabetes Mellitus Up to 32 Weeks
ADA Scientific Sessions 2025 abstract13 Jun 2025